文献速递肾移植肾小球疾病

肾小球肾炎移植前免疫抑制不增加肾移植后感染风险

Infections Following Kidney Transplantation After Exposure to Immunosuppression for Treatment of Glomerulonephritis.
PubMed 文献 · Am J Kidney Dis · 2023-12-30

单中心回顾性队列研究纳入2005年1月至2020年5月肾移植受者,比较因肾小球肾炎接受移植前免疫抑制治疗者(184例)与未接受者(579例)移植后感染风险。中位随访5.7年,调整混杂因素后,移植前免疫抑制未增加病毒(BK或CMV)或细菌感染风险。

要点

  • 移植前因肾小球肾炎使用免疫抑制未增加移植后病毒或细菌感染风险。
  • 不同移植前免疫抑制方案或T细胞清除诱导类型均不影响感染风险。
  • 接受移植前免疫抑制的患者可能无需额外感染监测或药物调整。

核心结论

  • 因肾小球肾炎接受移植前免疫抑制治疗与肾移植后病毒(BK或CMV)或细菌感染风险增加无关。
  • 接受移植前免疫抑制的患者可能无需额外的移植后感染监测。

研究设计与样本

  • 单中心回顾性队列研究,纳入2005年1月至2020年5月在某三级大学教学医院接受肾移植的受者。
  • 暴露组为因肾小球肾炎接受移植前免疫抑制治疗的患者(n=184),对照组为非糖尿病且未接受移植前免疫抑制的肾移植受者(n=579)。

主要发现

  • 中位随访5.7年,移植前免疫抑制组任何首次病毒感染风险未增加(调整HR 0.69,95%CI 0.52-0.91)。
  • BK感染发生率19.6% vs 26.3%(调整HR 0.72,95%CI 0.50-1.05),CMV感染24.5% vs 29.0%(调整HR 0.76,95%CI 0.54-1.07)。
  • 首次细菌感染发生率54.5% vs 57.5%(调整HR 0.90,95%CI 0.71-1.13)。
  • 上述无感染风险增加的结果与移植前免疫抑制类型(环磷酰胺、利妥昔单抗、吗替麦考酚酯或钙调神经磷酸酶抑制剂)或T细胞清除诱导类型(阿仑单抗或抗胸腺细胞球蛋白)无关。

临床怎么用

  • 对于因肾小球肾炎接受移植前免疫抑制治疗的肾移植受者,无需仅因感染担忧而加强移植后监测或调整药物。

局限性

  • 单中心研究,缺乏甲泼尼龙用于移植前免疫抑制治疗的数据,存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Kidney transplant patients with glomerulonephritis (GN) as their native disease commonly have received pretransplant immunosuppression (PTI). This may contribute to the immunosuppression burden potentially increasing the risk for infections after transplantation. STUDY DESIGN: Single-center, retrospective cohort study. SETTING & PARTICIPANTS: Recipients of a kidney transplant from January 2005 until May 2020 at a tertiary care university teaching hospital. EXPOSURE: Patients with GN as their native kidney disease who received PTI for treatment of GN (n=184) were compared with nondiabetic recipients of kidney transplants who did not receive PTI (n = 579). OUTCOME: First occurrence after transplantation of an infection outcome, either viral (BK or cytomegalovirus [CMV] infection) or bacterial. ANALYTICAL APPROACH: Cox regression analysis adjusted for age at transplant, sex, race, donor type, year of transplant surgery, dialysis vintage, receipt of T-cell depleting induction, and CMV transplant status. RESULTS: Over a median follow-up period of 5.7 years, patients with GN PTI were not at an increased risk for developing any first viral infection compared with controls (adjusted HR [AHR] 0.69 [95% CI, 0.52-0.91]) nor at increased risk for specific viral infections: BK infection 19.6% vs 26.3% (AHR 0.72 [95% CI, 0.50-1.05]) or CMV infection, 24.5% vs 29.0% (AHR, 0.76 [95% CI, 0.54-1.07]), respectively. There was also no increased risk of developing a first bacterial infection: 54.5% vs 57.5% (AHR, 0.90 [95% CI, 0.71-1.13]). These findings of no increased risk for infection were independent of the type of PTI used (cyclophosphamide, rituximab, mycophenolate mofetil, or calcineurin inhibitor) or the type of T-cell depleting induction therapy (alemtuzumab or antithymocyte globulin) administered. LIMITATIONS: Single-center study, no data on methylprednisone use for PTI, unmeasured confounding. CONCLUSIONS: Use of PTI for the treatment of GN was not associated with an increased risk of viral (BK or CMV) or bacterial infection after transplantation. Additional surveillance for infection after transplantation for patients who received PTI may not be necessary. PLAIN-LANGUAGE SUMMARY: Many kidney transplant patients have glomerular disease as the cause of kidney failure. These patients may be exposed to immunosuppression before transplantation, which could increase the risk for infections after receipt of a transplanted kidney. We identified kidney transplant recipients at a university teaching hospital who received immunosuppression before transplant for the treatment of glomerular kidney disease. We examined their risk for infection after transplantation by comparing it with the risk among transplant patients who were not exposed to immunosuppression before transplant. We observed no increased risk for infection after exposure to prior immunosuppression. Therefore, patients exposed to significant amounts of immunosuppression before transplantation may not require special surveillance or medication adjustment for fear of infection after their receipt of a kidney transplant.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Massicotte-Azarniouch D, Detwiler RK, Hu Y, et al. Infections Following Kidney Transplantation After Exposure to Immunosuppression for Treatment of Glomerulonephritis. Am J Kidney Dis. 2023. PMID: 38160700. doi:10.1053/j.ajkd.2023.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。